Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Aug;12(15):1769-81.
doi: 10.2217/fon-2016-0084. Epub 2016 Apr 27.

Obinutuzumab for the treatment of indolent lymphoma

Jennifer Edelmann  1 , John G Gribben  1
Affiliations
Review

Obinutuzumab for the treatment of indolent lymphoma

Jennifer Edelmann et al. Future Oncol. 2016 Aug.

Abstract

Obinutuzumab is a humanized, type II anti-CD20 monoclonal antibody designed for strong induction of direct cell death and antibody-dependent cell-mediated cytotoxicity. The Phase III GADOLIN trial tested the clinical efficacy of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy in rituximab-refractory indolent non-Hodgkin lymphoma versus treatment with bendamustine alone. It demonstrated significantly longer progression-free survival for the obinutuzumab-containing regimen in this difficult to treat patient group. Based on the results of this trial, US FDA approval was most recently granted for obinutuzumab in the treatment of follicular lymphoma that has relapsed after or was refractory to a rituximab-containing regimen. This article summarizes the available data on chemistry, pharmacokinetics, clinical efficacy and safety of obinutuzumab in the treatment of indolent non-Hodgkin lymphoma.

Keywords: anti-CD20 monoclonal antibody; efficacy; indolent lymphoma; obinutuzumab; rituximab-refractoriness; safety.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosures

JG Gribben has received honoraria from Roche/Genentech, Celgene, Janssen, Pharmacyclics, AbbVie, TG Therapeutics, and A2 for advisory boards and speaking. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Figures

<b>Figure 1.</b>
Figure 1.. Mechanisms of action of obinutuzumab.
Whereas the ability to induce ADCC and direct cell death is enhanced, obinutuzumab is less capable to induce CDC compared with type I anti-CD20 monoclonal antibodies such as rituximab and ofatumumab. ADCC: Antibody-dependent cell-mediated cytotoxicity; CDC: Complement-dependent cytotoxicity.
<b>Figure 2.</b>
Figure 2.. CD20 binding sites for obinutuzumab, rituximab and ofatumumab.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Hiddemann W, Cheson BD. How we manage follicular lymphoma. Leukemia. 2014;28(7):1388–1395. - PubMed
    1. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106(12):3725–3732. - PubMed
    1. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J. Clin. Oncol. 2008;26(28):4579–4586. - PubMed
    1. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood. 2008;112(13):4824–4831. - PubMed
    1. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a Phase 3, randomised controlled trial. Lancet. 2011;377(9759):42–51. - PubMed

MeSH terms

LinkOut - more resources